Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer and is currently pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older. In addition, the company is advancing its kinase-inhibitor pipeline of novel targeted therapies into the clinic.
Companies To Watch
XXII 1.45 N/A CKPT 9.00 N/A CPHR 2.99 N/A CFRX 1.25 N/A CRBP 5.80 N/A DMPI 2.12 N/A DVAX 9.25 N/A FBIO 4.48 N/A KERX 7.06 N/A MTNB 1.24 N/A MDGN 5.57 N/A MNOV 5.22 N/A MTFB 7.59 N/A PRQR 5.15 N/A STML 9.75 N/A SYN 0.501 N/A TGTX 11.55 N/A THLD 0.50 N/A TNXP 3.90 N/A URGN 18.40 N/A VSTM 3.60 N/A ZIOP 5.65 N/A 2017-07-27 15:59